Macquarie: VITASOY INT'L (00345) "Outperform" rating, target price lowered to 6.9 Hong Kong dollars.
McKinsey has downgraded the profit forecast for Vitamilk International for the fiscal years 2025, 2026, and 2027 by 38%, 38%, and 30% respectively.
Macquarie released a research report stating that VITASOY INT'L (00345) is rated as "outperforming the market," with profit forecasts for the fiscal years 2025 to 2027 being reduced by 38%, 38%, and 30% respectively to account for adverse weather conditions, market competition, and operational deleveraging factors. The target price for Vitasoy has been lowered by 27% to 6.9 Hong Kong dollars.
The report states that although the beverage market is challenging, it is still expected that VITASOY INT'L's revenue in the first half of the 2025 fiscal year will increase by 2.2%, and operating profit will increase by 9.3% year-on-year. The group has been unable to escape the impact of adverse weather conditions and market competition in the mainland market, but the performance in the Hong Kong market remains resilient.
 Related Articles 

The Pacific Shpping (02343) spent 26.09 million Hong Kong dollars on November 4 to repurchase 10 million shares.

China Communications Construction Company (01800) had repurchased a total of 15.5712 million A-shares by the end of October.

Yuexiu Property (00123) accumulated contract sales of approximately 92.102 billion yuan in the first 10 months, a year-on-year increase of about 1.2%.
The Pacific Shpping (02343) spent 26.09 million Hong Kong dollars on November 4 to repurchase 10 million shares.

China Communications Construction Company (01800) had repurchased a total of 15.5712 million A-shares by the end of October.

Yuexiu Property (00123) accumulated contract sales of approximately 92.102 billion yuan in the first 10 months, a year-on-year increase of about 1.2%.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


